Apo-Transferrin Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-43440
Key Product Details
Species Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Format
BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
Full-length Apo-Transferrin
Clonality
Polyclonal
Host
Rabbit
Description
Novus Biologicals Rabbit Apo-Transferrin Antibody - BSA Free (NBP3-43440) is a polyclonal antibody validated for use in IHC and WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
Applications for Apo-Transferrin Antibody - BSA Free
Application
Recommended Usage
Western Blot
0.01-2ug/mL
Formulation, Preparation, and Storage
Purification
Antigen and protein A Affinity-purified
Formulation
0.01M PBS, pH7.4, 50% glycerol.
Format
BSA Free
Preservative
0.05% Proclin 300
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Apo-Transferrin
Human Transferrin is synthesized as a 698 amino acid (aa) precursor that is divided into a 19 aa signal sequence plus a 679 aa mature segment that contains 19 intrachain disulfide bonds. Apo-Transferrin (iron-free) initially binds iron at the C-terminus, followed by iron binding at the N-terminus to form Holo-Transferrin (diferric-Transferrin). Holo-Transferrin will interact with the type I Transferrin receptor (TfR) on the surface of cells where it is internalized into acidified endosomes.
Alternate Names
ApoTransferrin
Additional Apo-Transferrin Products
Product Documents for Apo-Transferrin Antibody - BSA Free
Product Specific Notices for Apo-Transferrin Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...